Sangamo Therapeutics, Inc. (SGMO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Sangamo Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Sangamo Therapeutics, Inc. (SGMO) has returned -41.21% so far this year and -62.35% over the past 12 months. Over the last ten years, SGMO has returned -27.57% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Apr 6, 2000, SGMO's average daily return is +0.09%, while the average monthly return is +2.14%. At this rate, your investment would double in approximately 2.7 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jun 2000 with a return of +317.1%, while the worst month was Nov 2008 at -68.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.

On a daily basis, SGMO closed higher 47% of trading days. The best single day was May 11, 2017 with a return of +60.9%, while the worst single day was Nov 11, 2008 at -65.5%.

Sangamo Therapeutics, Inc. has an annualized alpha of 12.64%, beta of 1.55, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since April 07, 2000.

• This stock captured 217.13% of S&P 500 Index gains and 211.36% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SGMO ranks 11 for risk / return — in the bottom 11% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Sangamo Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sangamo Therapeutics, Inc. was 99.50%, occurring on Mar 31, 2026. The portfolio has not yet recovered.

The current Sangamo Therapeutics, Inc. drawdown is 99.50%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Sangamo Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Sangamo Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.